Hard Questions

Aftermath

Publish date: February 1, 2019

 

Dr. Yurkiewicz is a fellow in hematology and oncology at Stanford (Calif.) University. Follow her on Twitter @ilanayurkiewicz.

Pages

Recommended Reading

Should doctors disclose preliminary results?
MDedge Hematology and Oncology
Survivors of childhood Hodgkin lymphoma face 14-fold risk of second cancers
MDedge Hematology and Oncology
Lack of gut diversity hurts survival after HCT
MDedge Hematology and Oncology
Higher AML, MDS risk linked to solid tumor chemotherapy
MDedge Hematology and Oncology
Poor-prognosis cancers linked to highest suicide risk in first year
MDedge Hematology and Oncology
Soy didn’t up all-cause mortality in breast cancer survivors
MDedge Hematology and Oncology
Daily News Special: SABCS
MDedge Hematology and Oncology
Checkpoint inhibitors linked to rare, but serious immune-related side effects
MDedge Hematology and Oncology
HBV, HCV, HIV testing of new cancer patients advised
MDedge Hematology and Oncology
#Patients looking for #clinicaltrials
MDedge Hematology and Oncology